Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.80 +1.6%	$36.82	$23.42 ▼ $62.58	$2.25B	0.8	966,978 shs	722,567 shs
DNLI Denali Therapeutics	$15.49 +1.7%	$14.31	$10.57 ▼ $33.33	$2.26B	1.36	1.74 million shs	2.74 million shs
IRON Disc Medicine	$60.35 +1.0%	$56.87	$30.82 ▼ $68.73	$2.10B	0.77	332,509 shs	349,244 shs
PGEN Precigen	$4.18 +14.8%	$1.87	$0.65 ▼ $4.21	$1.25B	1.87	14.30 million shs	24.18 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+1.57%	+4.84%	-4.34%	+30.20%	-17.62%
DNLI Denali Therapeutics	+1.71%	+5.37%	+7.05%	+15.42%	-38.04%
IRON Disc Medicine	+1.00%	+0.82%	-0.97%	+27.40%	+22.39%
PGEN Precigen	+14.84%	+42.18%	+151.81%	+205.11%	+251.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3677 of 5 stars	3.4	2.0	4.3	2.9	0.8	1.9
DNLI Denali Therapeutics	4.2072 of 5 stars	3.6	1.0	4.7	3.1	3.3	0.0
IRON Disc Medicine	3.6995 of 5 stars	4.5	3.0	0.0	3.5	2.5	0.0
PGEN Precigen	3.883 of 5 stars	3.4	0.0	4.7	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	45.19% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.62	117.01% Upside
IRON Disc Medicine	3.09	Buy	$98.30	62.88% Upside
PGEN Precigen	2.80	Moderate Buy	$8.25	97.37% Upside

Current Analyst Ratings Breakdown

Latest PGEN, AGIO, IRON, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	PGEN Precigen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/19/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$6.00 ➝ $8.00
8/19/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.50
8/18/2025	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$33.00 ➝ $30.00
8/18/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$85.00 ➝ $90.00
8/15/2025	PGEN Precigen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral
8/13/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/21/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	61.76	N/A	N/A	$23.57 per share	1.65
DNLI Denali Therapeutics	$330.53M	6.85	N/A	N/A	$7.02 per share	2.21
IRON Disc Medicine	N/A	N/A	N/A	N/A	$17.67 per share	N/A
PGEN Precigen	$3.92M	317.73	N/A	N/A	($0.12) per share	-34.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.53	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.80	N/A	N/A	N/A	N/A	-40.79%	-36.39%	11/5/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$4.47	N/A	N/A	N/A	N/A	-26.60%	-24.58%	11/11/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.42	N/A	N/A	N/A	-2,868.66%	-842.83%	-78.98%	N/A

Latest PGEN, AGIO, IRON, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PGEN Precigen	-$0.14	-$0.11	+$0.03	-$0.09	$0.67 million	$0.86 million
8/11/2025	Q2 2025	DNLI Denali Therapeutics	-$0.74	-$0.72	+$0.02	-$0.72	$5.64 million	N/A
8/7/2025	Q2 2025	IRON Disc Medicine	-$1.17	-$1.58	-$0.41	-$1.58	N/A	N/A
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
DNLI Denali Therapeutics	0.01	10.27	10.27
IRON Disc Medicine	0.05	32.11	32.11
PGEN Precigen	N/A	2.71	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
DNLI Denali Therapeutics	92.92%
IRON Disc Medicine	83.70%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
DNLI Denali Therapeutics	12.50%
IRON Disc Medicine	3.64%
PGEN Precigen	47.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
DNLI Denali Therapeutics	430	146.21 million	127.94 million	Optionable
IRON Disc Medicine	30	34.77 million	33.50 million	Not Optionable
PGEN Precigen	190	297.97 million	157.63 million	Optionable

PGEN, AGIO, IRON, and DNLI Headlines

Recent News About These Companies

Precigen Inc. (PGEN) Stock Price Today - WSJ

August 22 at 6:09 PM | wsj.com

Cantor Fitzgerald Cuts Earnings Estimates for Precigen

August 22 at 8:16 AM | marketbeat.com

Precigen Target of Unusually High Options Trading (NASDAQ:PGEN)

August 22 at 4:07 AM | americanbankingnews.com

Precigen (NASDAQ:PGEN) Trading Up 10.9% After Analyst Upgrade

August 21 at 10:44 AM | marketbeat.com

Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 21 at 10:25 AM | marketbeat.com

Precigen (PGEN) Gets a Buy from Cantor Fitzgerald

August 21 at 10:24 AM | theglobeandmail.com

Precigen (NASDAQ:PGEN) Given New $8.00 Price Target at JMP Securities

August 21 at 9:13 AM | marketbeat.com

Precigen (NASDAQ:PGEN) Earns Buy Rating from HC Wainwright

August 21 at 8:10 AM | marketbeat.com

FY2026 EPS Estimates for Precigen Decreased by Analyst

August 21 at 3:10 AM | americanbankingnews.com

Precigen files to sell 143.81M shares of common stock for holders

August 20 at 5:32 PM | msn.com

Precigen (NASDAQ:PGEN) Sees Large Volume Increase - Still a Buy?

August 20 at 1:51 PM | marketbeat.com

Mill Creek Capital Advisors LLC Grows Stock Position in Precigen, Inc. $PGEN

August 20 at 6:55 AM | marketbeat.com

Precigen (NASDAQ:PGEN) Given Buy Rating at HC Wainwright

August 20 at 3:29 AM | americanbankingnews.com

JMP Securities Issues Positive Forecast for Precigen (NASDAQ:PGEN) Stock Price

August 20 at 2:12 AM | americanbankingnews.com

Precigen (NASDAQ:PGEN) Trading 10.9% Higher After Analyst Upgrade

August 20 at 2:35 AM | americanbankingnews.com

Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment

August 19, 2025 | insidermonkey.com

Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment

August 19, 2025 | msn.com

Citizens JMP Reaffirms Their Buy Rating on Precigen (PGEN)

August 19, 2025 | theglobeandmail.com

Promising Penny Stocks To Consider - August 17th

August 19, 2025 | marketbeat.com

Precigen price target raised to $8 from $6 at Citizens JMP

August 19, 2025 | msn.com

FY2025 EPS Estimates for Precigen Reduced by HC Wainwright

August 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PGEN, AGIO, IRON, and DNLI Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.80 +0.60 (+1.57%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$38.81 +0.01 (+0.02%)

As of 08/22/2025 05:51 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$15.49 +0.26 (+1.71%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.56 +0.07 (+0.48%)

As of 08/22/2025 07:34 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Disc Medicine NASDAQ:IRON

$60.35 +0.60 (+1.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$61.00 +0.65 (+1.08%)

As of 08/22/2025 05:45 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Precigen NASDAQ:PGEN

$4.18 +0.54 (+14.84%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.14 -0.04 (-0.84%)

As of 08/22/2025 07:59 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time